Cellexus Launches 50 Litre Single-Use, Disposable Bioreactor System

Cellexus Ltd, is captivated to advertise the availability of the 50 litre CellMaker Regular™, a individual use, disposable bioreactor arrangement for the announcement of oxygen-hungry protein pichia, E. Coli and algae. Designed to bear college optical densities (ODs) and bigger yields of acrid protein over alembic developed cultures, the addition of the 50 litre architecture follows the acknowledged barrage of the CellMaker Regular 8 litre arrangement in October 2008.

The CellMaker Regular alternation of articles use CellexusBags™ which are unique, single-use, disposable corpuscle ability accoutrements acceptance fast start-up times and eliminating diffuse charwoman protocols. Whereas added disposable systems crave shakers, rockers, rollers or ample ecology chambers, the CellMaker Regular ambit of articles apply proprietary airlift technology to calmly mix, aerate and advance corpuscle suspension. The systems are simple, scalable and bargain to use. The CellMaker Regular Controller units accredit absolute administration of temperature (15 to 45⁰C), bag-pressure and breeze of air and oxygen into the corpuscle culture. Accurate ascendancy of these ambit enables optimisation of ability advance and bigger announcement levels of acrid protein.

Mr Bob Cumming, General Manager of Cellexus Limited, declared “We are actual admiring to aggrandize the ambit of CellMaker Regular articles to add the 50 litre arrangement to the 8 litre arrangement we launched some months ago. It provides our users with added scalability and illustrates our charge to affair chump needs with our concerted artefact development action advised to added facilitate arrangement use and performance.”

Cellexus provides a ambit of instruments and amount added consumables to advice advisers in the biopharmaceutical industry and academia advance new biopharmaceutical articles from corpuscle lines. Biopharmaceuticals are a rapidly evolving ambit of analysis generated by culturing beef in bioreactors and cover proteins, antibodies or vaccines, with the accessible of approaching medical treatments offered by axis corpuscle analysis aswell falling into this category. Sales of biopharmaceuticals accomplished US$60 billion in 2005 and are growing at 20% per year.

The Company’s amount technology is at the centre of a ambit of altered artefact configurations and formats the Company offers that can be acclimated for assembly of biological beef and proteins in a single-use bag format. This aforementioned agreement can aswell be acclimated in biopharmaceutical accomplish for bond assorted abstracts beneath apple-pie and antiseptic conditions. These artefact ambit action cogent abstruse improvements for corpuscle ability and corpuscle advance to the biopharmaceutical industry.

The single-use (consumable) elements of the CellMaker bioreactors the Company markets are the CellexusBag™ and HybridBag. These individual use cocky absolute accoutrements anatomy a artefact ambit (there are currently six variants of the CellexusBag™ and two variants of the HybridBag) which are bogus beneath apple-pie allowance altitude and to the ISO standards appropriate by the biopharmaceutical industry. The bioreactor articles appear with complete alarming units and an oxygen generator, which removes the charge for piped gas. The affable breeze of gas bubbles mixes the capacity and the bag architecture reduces foaming. The CellMaker accessories acclimated to administer the corpuscle ability action is actual simple, able and bargain to use. A apparent attention the Company’s Intellectual Property in this across was filed in December 2005 with a additional apparent appliance filed in June 2007.